TGFB2 and neoplasm: Of these nine genes, the highest levels of expression in tumor tissue were observed for CD74 (Mean ± SEM = 10.94 ± 0.08; 21.8-fold increase relative normal tissue), IFI27 (9.63 ± 0.12; 66.3-fold increase), and HLA-DRA (9.3 ± 0.1; 31-fold increase) for potential use as biomarkers for PDAC prognosis, whereby low levels of expression of these TAM markers would increase the susceptibility of PDAC patients for anti-TGFB2 mRNA directed therapies.